廖剑敏　冯钢　李姣　张倩

【摘 要】目的：探讨布地奈德混悬液雾化吸入治疗成人肺炎支原体感染后慢性咳嗽的临床效果。方法：选取2015年6月至2018年6月于我院进行治疗的肺炎支原体肺炎后慢性咳嗽患者共计88例，根据患者的就诊时间将其分为观察组和对照组，对照组患者使用氨溴索注射液进行雾化吸入治疗，观察组患者则使用布地奈德混悬液进行雾化吸入治疗，对比两组患者的临床疗效。结果：观察组患者的临床咳嗽评分较之对照组要更低，观察组患者的临床治疗效果要好于对照组，差异具有统计学意义（p<0.05）。结论：在肺炎支原体肺炎感染后慢性咳嗽的治疗中，应用布地奈德混悬液雾化吸入治疗具有较好的临床疗效，值得推广使用。

【关键词】布地奈德；肺炎支原体；肺炎；慢性咳嗽

Clinical effect of nebulization inhalation of budesonideon chronic cough after Mycoplasma pneumoniae infection

Abstract：Objective To investigate the clinical effect of nebulization inhalation of budesonide on chronic cough after Mycoplasma pneumoniae infection. Methods： 88 patients with chronic cough after Mycoplasma pneumoniae infection who were treated in our hospital from June 2015 to June 2018 were divided into observation group and control group according to their visiting time. The control group was treated with ambroxol injection and the observation group was treated with budesonide suspension. inhalation treatment， compared the clinical efficacy of two groups of patients. Results： The clinical cough score of the observation group was lower than that of the control group， and the therapeutic effect of the observation group was better than that of the control group （P < 0.05）. Conclusion： In the treatment of chronic cough after Mycoplasma pneumoniae infection， use of budesonide inhalation therapy has better clinical efficacy， it is worth popularizing.

Key words： Budesonide；Mycoplasma pneumoniae ；pneumonia；chronic cough

【中圖分类号】R725.6 【文献标识码】B 【文章编号】1005-0019（2018）22-0-01

社会的快速发展，引发居住及生活环境剧烈的变化，从而引发人们生活习惯中逐渐增多的不良喜好及不规律作息，肺部感染性疾病的发病率显著增加，尤其是成人肺炎支原体肺炎的发病率呈现出明显上升的趋势，已经超过肺炎链球菌成为成人社区获得性肺炎的第一位致病菌[1]。在我国秋冬寒冷季发病率较高，全年龄段可见，尤其以50岁以下年龄段多见[1]。肺炎支原体肺炎临床多表现为干咳，在临床观察中，部分患者在经过积极及有效的治疗后，影像学上肺炎部分或完全吸收后，依旧存在慢性咳嗽的情况，且使用一般止咳药物疗效欠佳。在儿童支原体肺炎中大量研究显示显示布地奈德混悬液雾化吸入治疗对于儿童患者咳嗽具有明显效果[2]，那么此药物在成人该症患者感染后的慢性咳嗽的治疗效果如何，本次研究就对此进行了探讨分析，详细内容如下。……